Claims for Patent: 10,145,843

Summary for Patent: 10,145,843

Title:	Magnetic immunosensor and method of use
Abstract:	The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.
Inventor(s):	Miller; Cary James (Ottawa, CA), Hu; Jinghua (Ottawa, CA)
Assignee:	Abbott Point of Care Inc. (Princeton, NJ)
Application Number:	15/938,141
Patent Claims:	1. A magnetic immunosensing device, comprising: a sensing electrode on a substantially planar chip, wherein the electrode is positioned in a conduit for receiving a sample mixed with antibody-labeled magnetically susceptible beads; and a microfabricated magnetic layer, wherein the microfabricated magnetic layer comprises high-field permanent magnetic particles dispersed in a thermally, chemically, or photoformably cured immobilization matrix, wherein the immobilization matrix comprises a polyimide, polyvinyl alcohol, or epoxy resin, wherein the magnetic layer is positioned relative to the electrode, thereby attracting the beads substantially proximate to the electrode and substantially retaining the beads at the electrode surface during removal of unbound sample and washing of the electrode. 2. The device of claim 1, wherein the electrode and/or the magnetic layer is microfabricated. 3. The device of claim 1, wherein the sample is selected from the group consisting of blood, plasma, serum, urine, interstitial fluid and cerebrospinal fluid. 4. The device of claim 1, wherein the sample is amended with an anticoagulant. 5. The device of claim 1, wherein the high-field permanent magnetic particles comprise a neodymium iron boron (NdFeB) alloy. 6. The device of claim 1, wherein the high-field permanent magnetic particles comprise a Nd.sub.2Fe.sub.14B alloy. 7. The device of claim 1, wherein the magnetic layer provides a magnetic field of greater than about 0.1 Tesla. 8. The device of claim 1, wherein the magnetic layer is positioned to yield an event horizon in the conduit in the range of up to about 200 .mu.m in the region of the electrode. 9. The device of claim 1, wherein the beads comprise ferrite, magnetite (Fe.sub.3O.sub.4), and/or a magnetically susceptible core with a polymer coating. 10. The device of claim 1, wherein the beads have an average particle size of from 0.01 .mu.m to 20 .mu.m. 11. The device of claim 1, wherein the beads dissolve from a dry matrix into the sample. 12. The device of claim 1, wherein over 50 wt. % of the beads are retained at the electrode surface. 13. The device of claim 1, wherein the electrode is amperometric and/or a gold microarray. 14. The device of claim 1, wherein the conduit has a height of about 0.2 mm to about 5 mm and a width of about 0.2 mm to about 5 mm. 15. The device of claim 1, wherein the conduit has a uniform cross-sectional area. 16. The device of claim 1, wherein the conduit has a non-uniform cross-sectional area. 17. The device of claim 1, wherein the antibody is to a low-abundance analyte in the sample. 18. The device of claim 1, wherein the antibody is to an analyte selected from the group consisting of cardiac troponin I, troponin T, a troponin complex, human chorionic gonadotropin, BNP, creatine kinase, creatine kinase subunit M, creatine kinase subunit B, creatine kinase MB (CK-MB), proBNP, NT-proBNP, myoglobin, myosin light chain and modified fragments thereof. 19. The device of claim 1, wherein the antibody is to an analyte selected from the group consisting of beta-HCG, TSH, ultra hTSH II, TT3, TT4, FT3, FT4, myeloperoxidase, D-dimer, CRP, NGAL, PSA, LH, FSH, prolactin, progesterone, estradiol, DHEA-S, AFP, CA 125 II, CA 125, CA 15-3, CA 19-9, CA 19-9XR, CEA, thyroxine (T4), triiodothyronine (T3), T-uptake, Tg, anti-Tg, anti-TPO, ferritin, cortisol, insulin, HBsAg, HCV Ag/Ab combo, HCV core Ag, anti-HCV, AUSAB (anti-HBs), CORE, CORE-M, SHBG, iPTH, theophylline, sirolimus, tacrolimus, anti-HAV, anti-HAV IgM, HAVAB, HAVAB-M, HAVAB-M2.0, HAVAB-G, HAVAB 2.0, HAVAB 2.0 Quant, IgM, CMV IgM, CMV IgG, digitoxin, HBe, anti-HBe, HBeAg, HIV 1/2gO, HIV Ag/Ab combo, testosterone, SCC, vitamin B12, folate, syphilis, anti-HBc, rubella IgG, rubella IgM, homocysteine, MPO, cytomegalovirus (CMV) IgG Avidity, toxo IgG avidity, toxo IgG, toxo IgM, C-peptide, vitamin D, HTLV I/II, total ahCG, progesterone, estradrogen, prolactin, myoglobin, tPSA, fPSA, carbamazepine (CBZ), digoxin, gentamicin, NAPA, phenytoin, phenobarbital, valproic acid, vancomycin, procaine, quinidine, tobramycin, methamphetamine (METH), amphetamine (AMPH), barbiturates, benzodiazepine, cannabis, cocaine, methadone, opiates, PCP, acetaminophen, ethanol, salicylates, tricyclics, holoTc, anti-CCP, HbA1c, barbs-U and modified fragments thereof. 20. The device of claim 1, wherein the washing of the electrode is performed with a wash fluid applied as at least one meniscus.

Details for Patent 10,145,843

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2038-03-28
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2038-03-28
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2038-03-28
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990		2038-03-28